Jubilant Cadista Pharmaceuticals, Inc. has recalled approximately 14,544 bottles of Donepezil HCL (donepezil hydrochloride) tablets, which is a generic medication used to treat dementia and symptoms of Alzheimer's disease. The recall was issued because testing revealed the tablets were subpotent, meaning they may not contain the full required amount of the active ingredient. This recall affects 5 mg strength tablets sold in 90-count bottles that were distributed nationwide. If you have this medication, you should consult with your healthcare provider or pharmacist to ensure your treatment remains effective.
Subpotent medication contains less of the active ingredient than prescribed, which can lead to a decrease in the medication's effectiveness. For patients with Alzheimer's, this could result in a temporary loss of symptom control or a lack of expected improvement.
AI-Enhanced Content: The summary, action steps, and risk assessment on this page were generated by AI from official government recall data to improve readability. This is not legal or medical advice. Always refer to the official agency sources below for authoritative information.
Sources: FDA iRES · Raw API Response
openFDA Disclaimer: This recall information is sourced from the openFDA API. Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. Refer to the openFDA terms of service for more information.